Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - testosteronum - gel - testosteronum 1.71 g, propylenglycolum, excipiens annuncio gelatum. - ipogonadismo maschile - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - polysaccharida haemophili influenzae typus b conjugata cum proteino neisseriae meningitidis b, hepatitidis b viri antigenum adnr, toxoidum pertussis, haemagglutininum filamentosum, pertactinum, fimbriae typ 2 und 3, toxoidum diphtheriae, toxoidum tetani, virus poliomyelitis typus 1 inactivatus (mahoney), virus poliomyelitis typus 2 inactivatus (mef-1), virus poliomyelitis typus 3 inactivatus (saukett) - sospensione iniettabile - polysaccharida haemophili influenzae typus b conjugata cum proteino neisseriae meningitidis b 53 µg corresp. polysaccharida haemophili influenzae typus b 3 µg et neisseria meningitidis b outer membrane protein complex 50 µg, hepatitidis b viri antigenum adnr 10 µg, toxoidum pertussis 20 µg, haemagglutininum filamentosum 20 µg, pertactinum 3 µg, fimbriae typ 2 und 3 5 µg, toxoidum diphtheriae min. 20 u.i., toxoidum tetani min. 40 u.i., virus poliomyelitis typus 1 inactivatus (mahoney) 40 u., virus poliomyelitis typus 2 inactivatus (mef-1) 8 u., virus poliomyelitis typus 3 inactivatus (saukett) 32 u., aluminium ut aluminii phosphas et aluminii hydroxyphosphas sulfas amorphus, natrii phosphates, acidum hydrochloridum q.s. ad ph, natrii hydroxidum q.s. ad ph, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.95 mg, residui: glutaralum, formaldehydum, neomycinum, streptomycinum, polymyxinum b, albuminum seri bovis, aluminii thiocyanas, faecis proteina. - vaccinazione primaria e di richiamo nei neonati e nei bambini a partire dall'età di 6 settimane fino a 4 anni (prima del 5. compleanno) contro difterite, tetano, pertosse, epatite b, poliomielite e da haemophilus influenzae di tipo b (hib) ha provocato malattie invasive. - vaccini

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 8 mg, ethanolum anhydricum 15.31 mg, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.16 ml. - terapia sostitutiva in caso di dipendenza da oppiacei - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 16 mg, ethanolum anhydricum 30.62 mg, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.32 ml. - terapia sostitutiva in caso di dipendenza da oppiacei - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 24 mg, ethanolum anhydricum 45.94 mg, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.48 ml. - terapia sostitutiva in caso di dipendenza da oppiacei - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 32 mg, ethanolum anhydricum 61.25 mg, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.64 ml. - terapia sostitutiva in caso di dipendenza da oppiacei - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 64 mg, n-methylpyrrolidonum, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.18 ml. - terapia sostitutiva in caso di dipendenza da oppiacei - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 96 mg, n-methylpyrrolidonum, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.27 ml. - terapia sostitutiva in caso di dipendenza da oppiacei - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 128 mg, n-methylpyrrolidonum, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.36 ml. - terapia sostitutiva in caso di dipendenza da oppiacei - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - complexus toxini botulinici a et haemagglutinini - soluzione iniettabile - complexus toxini botulinici a et haemagglutinini 125 u., histidinum, saccharum, natrii chloridum corresp. natrium 2.156 mg, polysorbatum 80, acidum hydrochloricum q.s. ad ph pro vitro. - zur vorübergehenden verbesserung des erscheinungsbildes von mittelstarken bis starken glabellafalten beim stirnrunzeln bei erwachsenen patienten unter 65 jahren, wenn das ausmass dieser falten eine erhebliche psychische belastung für den patienten darstellt. - biotechnologika